Research map: Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies

Back to the article

Papers in this map

  1. Hallmarks of Cancer: The Next Generation · Douglas Hanahan · 2011 · 67934 citations · Cited by this paper
  2. Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives · 2026 · Related
  3. Sorafenib in Advanced Hepatocellular Carcinoma · Josep Maria Llovet · 2008 · 13127 citations · Cited by this paper
  4. Advancing Human Placental Modeling Through Stem-Cell-Derived Trophoblast Organoids and Reprogramming Innovations · 2026 · Related
  5. Hepatocellular carcinoma · Josep Maria Llovet · 2021 · 6739 citations · Cited by this paper
  6. The Role of Endothelial–Mesenchymal Transition (EndMT) in Aneurysm Formation · 2026 · Related
  7. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update · María Reig · 2021 · 4352 citations · Cited by this paper
  8. Ectoine Inhibits IL-1β-Induced Inflammation by Suppressing the NF-κB Pathway in Chondrocytes and Alleviates Osteoarthritis in a Rat Model · 2026 · Related
  9. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma · Ghassan K. Abou‐Alfa · 2018 · 2394 citations · Cited by this paper
  10. Differential Protective Actions of Dulaglutide and Dexamethasone in Methotrexate Induced Pulmonary Fibrosis: Relationship with AMPK and Beclin-1 Levels · 2026 · Related
  11. Molecular therapies and precision medicine for hepatocellular carcinoma · Josep Maria Llovet · 2018 · 2056 citations · Cited by this paper
  12. Evaluation of Early and Delayed Meloxicam Treatment Against Regulated Cell Death Pathways and ERK1/2 Phosphorylation in a Rat Model of Renal Ischemia–Reperfusion Injury · 2026 · Related
  13. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma · Amit G. Singal · 2023 · 1950 citations · Cited by this paper
  14. Overcoming mTOR Inhibitor Resistance: From Biological Basis to Therapeutic Strategies · 2026 · Related
  15. The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention · John J. O’Shea · 2015 · 1633 citations · Cited by this paper
  16. Region-Specific Proteomic Profiles of Extracellular Vesicles (EVs) Derived from Human Macular and Peripheral RPE-Choroid Explants · 2026 · Related
  17. Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5 · Li Liu · 2006 · 1556 citations · Cited by this paper
  18. Bioactive Metabolites of Solanum tuberosum L. in Inflammation Modulation and Tissue Regeneration: A Scoping Review of Wound Healing Mechanisms · 2026 · Related
  19. Emerging functions of the EGFR in cancer · Sara Sigismund · 2017 · 1517 citations · Cited by this paper
  20. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3‐kinase inhibitor BEZ235 and the PI3‐kinase inhibitor BKM120 in hepatocellular carcinoma · 2013 · Related
  21. ERK signalling: a master regulator of cell behaviour, life and fate · Hugo Lavoie · 2020 · 1262 citations · Cited by this paper
  22. Understanding MAPK Signaling Pathways in Apoptosis · Jicheng Yue · 2020 · 1255 citations · Cited by this paper
  23. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects · Weiwei Tang · 2020 · 1176 citations · Cited by this paper
  24. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial · Jordi Bruix · 2015 · 1130 citations · Cited by this paper
  25. Mechanisms of receptor tyrosine kinase activation in cancer · Zhenfang Du · 2018 · 1099 citations · Cited by this paper
  26. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis · Peter Charles Taylor · 2017 · 977 citations · Cited by this paper
  27. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges · Zhilin Zou · 2020 · 963 citations · Cited by this paper
  28. FGF/FGFR signaling in health and disease · Yangli Xie · 2020 · 928 citations · Cited by this paper
  29. Nanomedicine in cancer therapy · Dahua Fan · 2023 · 861 citations · Cited by this paper
  30. Targeted therapy for hepatocellular carcinoma · Ao Huang · 2020 · 788 citations · Cited by this paper
  31. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer · Le Yu · 2021 · 787 citations · Cited by this paper
  32. Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study · Philip James Johnson · 2013 · 781 citations · Cited by this paper
  33. Evolving therapeutic landscape of advanced hepatocellular carcinoma · Chen Guang Yang · 2022 · 746 citations · Cited by this paper
  34. Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma · Augusto Villanueva · 2008 · 738 citations · Cited by this paper
  35. Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours · J. Justin Milner · 2017 · 734 citations · Cited by this paper
  36. Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC · Diego Francesco Calvisi · 2006 · 732 citations · Cited by this paper
  37. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma · Andrew Xiuxuan Zhu · 2022 · 666 citations · Cited by this paper
  38. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study · Josep Maria Llovet · 2013 · 598 citations · Cited by this paper
  39. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update · Francesco Izzo · 2019 · 587 citations · Cited by this paper

Source: OpenAlex (CC0)